| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Universe Pharmaceuticals Inc$4.56
-0.35 (-7.04%)
Market Cap
1.62 M
EPS
-10.13
P/E Ratio
-
Value Trade
13.97 K
8.68 %
Week
-8.28 %
1 Month
-3.36 %
3 Month
-13.77 %
6 Month
-99.98 %
5 Year
-99.98 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
167.47 K
52 Week Range
2 - 11
% held by Insiders
48.34 %
% held by Institutions
4.45 %
Enterprise Value
-22.71 M
Total Shares
563.34 K
Short %
72.57 %
Float Shares
563.34 K
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Universe Pharmaceuticals Inc
3Total events
0Upcoming
1Tier-1 (high impact)
2026 – 2026Coverage
Event history 2
TBD
◆Timing GuidancePresentation
Subscribe to view catalyst details
TBD
◆AcquisitionCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in UPC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
UPC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
UPC▲ +311.5%on this news
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
Universe Pharmaceuticals INC has announced a strategic acquisition of Best Praise International Limited, acquiring five patents for $10.75 million. This move aims to enhance its pharmaceutical capabilities, particularly in elderly healthcare and related fields. The acquisition is expected to close in Q3 2026, pending customary conditions.
Read more →UPCUniverse Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure Ji'an, Jiangxi, China
Universe Pharmaceuticals INC has announced that its dual-class share structure will become effective on February 13, 2026. This includes a change in its authorized share capital to comprise Class A and Class B ordinary shares. The Class A shares will continue to trade under the symbol 'UPC' on the Nasdaq Capital Market. The company specializes in the production and distribution of pharmaceutical products, particularly traditional Chinese medicine targeting the elderly.
Read more →UPC▼ -5.4%on this news· ran to -18% by day 3
Universe Pharmaceuticals INC (an exempted company with limited liability incorporated in the Cayman Islands) (Nasdaq: UPC) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the annual general m
Universe Pharmaceuticals INC has announced the details of its upcoming annual general meeting, scheduled for August 26, 2025, in Jiangxi, China. Shareholders registered by the record date of July 18, 2025, will have the right to vote on several resolutions, including the election of directors and alterations to share capital. Proxy options are provided to facilitate participation for those who cannot attend in person. The meeting aims to enhance shareholder involvement in corporate governance.
Read more →UPC▼ -9.2%on this news
Universe Pharmaceuticals INC Announces Share Consolidation Jiangxi, China
Universe Pharmaceuticals INC has announced a plan for a share consolidation, converting 40 ordinary shares into one share with increased par value. This action, effective March 24, 2025, aims to streamline its share structure and potentially enhance liquidity for investors. Following the consolidation, the total authorized share capital will be $140,625,000, allowing for continued operations across its pharmaceutical and traditional medicine offerings. The company operates in 30 provinces in China and specializes in products targeting the aging population.
Read more →UPC▼ -6.1%on this news· ran to -20% by day 3
Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report Ji'an, Jiangxi, China
Universe Pharmaceuticals INC has received a staff determination notice from Nasdaq due to its failure to file its Annual Report on Form 20-F for the fiscal year ending September 30, 2024. This delinquency presents a risk of delisting from the stock exchange. The company intends to request a stay of suspension before the specified date and is actively working to complete the overdue report. This announcement is in compliance with Nasdaq's rules regarding deficiency notifications.
Read more →UPC▲ +9.5%on this news
Universe Pharmaceuticals INC (incorporated in the Cayman Islands with limited liability) (Nasdaq: UPC) NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT  the extraordinary general
Universe Pharmaceuticals INC has announced an extraordinary general meeting of shareholders scheduled for March 1, 2025. The meeting will focus on approving a proposed share consolidation, whereby shareholders will consolidate every 50 shares into one share. The board of directors has set January 28, 2025, as the record date for determining eligible shareholders. Management is actively soliciting proxy votes to ensure shareholder participation in the decision-making process.
Read more →UPCUniverse Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request Ji'an, Jiangxi, China
Universe Pharmaceuticals INC has received a delisting notice from Nasdaq due to its ordinary shares closing below $1 for 30 consecutive business days. The company cannot utilize the standard compliance period due to a recent reverse stock split. However, it plans to appeal the delisting determination by February 5, 2025, which will suspend the trading suspension until the hearing. If the appeal is not requested, trading of their shares will be suspended starting February 7, 2025.
Read more →UPC▼ -59.3%on this news· ran to -76% by day 3
Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering Jiangxi, China
Universe Pharmaceuticals INC has announced a definitive agreement for a registered direct offering, raising approximately $15 million by selling 18,750,000 ordinary shares at a price of $0.80 each. The offering includes warrants for the same number of shares with a five-year exercise term. This transaction is set to close on December 10, 2024, and is made possible through an effective shelf registration statement previously filed with the SEC. The company focuses on traditional Chinese medicine products, particularly for elderly consumers across China.
Read more →UPC▲ +5.5%on this news
Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Ji'an, Jiangxi, China
Universe Pharmaceuticals INC received a notification from the Nasdaq Stock Market about not meeting the minimum bid price requirement. The closing bid price of its ordinary shares fell below $1.00 for 30 consecutive business days. The company has until April 23, 2025, to regain compliance or face potential delisting. Despite this notice, the company's operations remain unaffected, and they are considering options to improve compliance.
Read more →UPCUNIVERSE PHARMACEUTICALS INC AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS As of
Universe Pharmaceuticals Inc. reported its condensed consolidated balance sheets and statements of income for the periods ending March 31, 2024, and March 31, 2023. The financial results indicate a substantial net loss of $13.1 million, a sharp decline in revenue from the previous year, and an increase in liabilities. The company's total assets decreased as compared to the previous reporting period, raising concerns regarding its financial health and operational effectiveness.
Read more →UPCUniverse Pharmaceuticals INC (incorporated in the Cayman Islands with limited liability) (Nasdaq: UPC) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT  the annual general meeting (the
Universe Pharmaceuticals Inc will hold its annual general meeting on September 27, 2024, in Ji'an City, China. The agenda includes re-electing several directors and proposals for increasing the company's authorized share capital. Shareholders of record as of September 4, 2024, are entitled to vote at the meeting. Management is soliciting proxies for shareholder participation in the decision-making process.
Read more →UPCUniverse Pharmaceuticals INC Reports Fiscal Year 2023 Financial Results Universe Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today...
Universe Pharmaceuticals INC reported its fiscal year 2023 financial results, revealing a 19.5% decline in total revenues to $32.3 million. Despite a net loss of $6.2 million, the company highlighted a 55.1% increase in sales volume of traditional Chinese medicine products. The CEO expressed confidence in future growth, particularly targeting the aging population in China.
Read more →UPCUNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) As of
Universe Pharmaceuticals Inc. reported its unaudited condensed consolidated balance sheets as of March 31, 2023, showing a total asset increase to approximately $70.4 million. Current assets rose significantly, driven mainly by an increase in cash and short-term investments. However, the company also reported a net loss of $715,427 for the six months ending March 31, 2023, highlighting challenges despite an overall rise in total assets. Operating expenses remain a concern as they overshadow the gross profit generated, raising questions about the company's financial stability moving forward.
Read more →UPCUniverse Pharmaceuticals INC Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares
Universe Pharmaceuticals INC received a notification from Nasdaq regarding its non-compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement. The company has 180 days to regain compliance, or it may face delisting. Despite this, the company's operations are not affected, and it plans to monitor its MVPHS closely.
Read more →UPCUniverse Pharmaceuticals INC Announces Share Consolidation
Universe Pharmaceuticals INC has announced a share consolidation plan, converting six ordinary shares into one. This consolidation will take effect on July 27, 2023, and will not require any action from shareholders. Following the consolidation, the company's shares will trade under the same symbol on the Nasdaq Global Market, albeit with a new CUSIP number.
Read more →UPCUniverse Pharmaceuticals INC (incorporated in the Cayman Islands with limited liability) (Nasdaq: UPC) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the annual general meeting (the “
Universe Pharmaceuticals INC has convened an annual general meeting scheduled for July 3, 2023, in Ji'an City, China. The agenda includes the re-election of directors and proposals for increasing the company’s authorized share capital. Shareholders must be on record as of May 24, 2023, to participate. The meeting aims to solidify leadership and enhance financial position, although changes may raise concerns among existing shareholders.
Read more →UPCUniverse Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Universe Pharmaceuticals INC has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company has until August 29, 2023, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The notification does not currently affect the company's listing status or operations.
Read more →UPCUniverse Pharmaceuticals INC Announces Inclusion of Six Products into the First Edition of Catalogue of Medicine for Patients Infected with COVID-19
Universe Pharmaceuticals INC announced that six of its products have been included in the First Edition of the Catalogue of Medicine for Patients Infected with COVID-19, published by the Beijing Health Commission. This inclusion is part of a broader effort to provide recommended medicines for various COVID-19 symptoms. The company is seeing increased demand for its products and is working to optimize its supply chain to ensure availability.
Read more →UPCUniverse Pharmaceuticals INC Regains Compliance with Nasdaq Minimum Bid Price Requirement
Universe Pharmaceuticals INC has announced that it has regained compliance with Nasdaq's minimum bid price requirement as of November 9, 2022. The company was previously notified of non-compliance on July 15, 2022, but has since maintained a closing bid price above $1.00 for the required period. This development allows the company to continue trading on the Nasdaq exchange without restrictions.
Read more →UPCUniverse Pharmaceuticals INC (incorporated in the Cayman Islands with limited liability) (Nasdaq: UPC) NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT the annual general meeting (the " Meetin
in the Cayman Islands with limited liability) OF ANNUAL GENERAL MEETING OF SHAREHOLDERS IS HEREBY GIVEN THAT the annual general meeting (the "Meeting") of holders of ordinary shares (the "Ordinary Shares") (the "shareholders") of (the "Company") will be held on September 23, 2
Read more →UPCINDEX TO FINANCIAL STATEMENTS UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES TABLE OF CONTENTS Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheets as of
TO FINANCIAL STATEMENTS PHARMACEUTICALS INC. AND SUBSIDIARIES Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheets as of March 31, 2022 and September 30, 2021 F-2 Unaudited Condensed Consolidated Statements of Income and Comprehensive Income for th
Read more →UPCUniverse Pharmaceuticals INC Announces Strategic Partnership with Lian-Ou Health to Develop its Digital Marketing and Sales on E-Commerce Platforms
Universe Pharmaceuticals INC has entered into a strategic partnership with Lian-Ou Health to enhance its digital marketing and e-commerce sales. This collaboration aims to leverage both companies' strengths in product promotion and customer service, addressing challenges posed by the COVID-19 pandemic. The agreement is expected to improve brand recognition and support sustainable growth.
Read more →UPCUniverse Pharmaceuticals INC Authorized as The International Branch of National Engineering Technology Research Center
Universe Pharmaceuticals INC has been authorized as an International Branch of the National Engineering Technology Research Center for Modernization of Traditional Chinese Medicine. This recognition allows the Company to leverage the Center's resources and expertise, enhancing its focus on traditional Chinese medicine. The authorization ceremony included key government and industry representatives, marking a significant milestone for the Company.
Read more →UPCUniverse Pharmaceuticals INC Reports Fiscal Year 2021 Financial Results
Universe Pharmaceuticals INC reported strong financial results for the fiscal year 2021, with revenues reaching $48 million and net income of $11.3 million. Despite facing challenges from the COVID-19 pandemic, the company expanded its sales network and invested heavily in research and development. Significant growth in both revenue and net income reflects the company's strategic focus on product quality and market expansion.
Read more →UPCUniverse Pharmaceuticals INC Announces Strategic Alliance with Jiangxi Province Institute of Materia Medica to Conduct Research on Traditional Chinese Medicine
Universe Pharmaceuticals INC has formed a strategic alliance with Jiangxi Province Institute of Materia Medica to conduct six studies on traditional Chinese medicine. The collaboration aims to enhance the quality standards of various herbal formula granules and improve R&D capabilities. This partnership is expected to create new business opportunities and improve the efficacy of existing pharmaceutical products.
Read more →UPCMANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our conso
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes that appe
Read more →UPCUniverse Pharmaceuticals INC Announces Full Exercise of Underwriter's Over-Allotment Option in the Public Offering Ji'an, Jiangxi, China
Universe Pharmaceuticals INC Announces Full Exercise of Underwriter's Over-Allotment Option in the Public Offering Ji'an, Jiangxi, China, March 31, 2021 - Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today anno
Read more →UPCUniverse Pharmaceuticals INC Announces Pricing and Trading of Initial Public Offering Ji'an, Jiangxi, China
Universe Pharmaceuticals INC Announces Pricing and Trading of Initial Public Offering Ji'an, Jiangxi, China, March 23, 2021 - Universe Pharmaceuticals INC (the "Company"), a pharmaceutical producer and distributor in China, today announced the pricing of its initial public of
Read more →Competitive Position
How UPC ranks across every disease it competes inCompetitive Position is a premium feature
See how UPC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial